"I am so fortunate to work in an environment filled with scientifically curious colleagues who are motivated by trying to solve any problems that stand in the way of bringing useful drugs to patients."
I joined Genentech in 2006 to establish a small molecule discovery toxicology group to enable lead optimization for candidate identification and an investigative toxicology laboratory for hypothesis-driven mechanistic evaluations. I am currently Head of Toxicology and oversee a group of scientists and staff that provides portfolio and program strategic and technical expertise from discovery through post-marketing for small molecules and biopharmaceuticals, including safety lead optimization and development candidate identification, the design and implementation of non-clinical development strategies for INDs/CTAs through NDAs/MAAs, and investigative toxicology support for programs through an Investigative Toxicology Laboratory.
Prior to joining Genentech, I worked in both academia and industry as a comparative anatomic pathologist and as a discovery and regulatory toxicologist, and have contributed in establishing the use of new technologies and lead optimization strategies for safety evaluation; identification of safety biomarkers; and the development of numerous drugs. I received my veterinary degree (V.M.D.) from the University of Pennsylvania in 1990, completed a residency in comparative anatomic pathology at the University of Pennsylvania and attained board certification (American College of Veterinary Pathology) as a diplomate in the subspecialty of Comparative Anatomic Pathology (1994). I received my Ph.D. from the Department of Toxicology from Rutgers University/University of Medicine and Dentistry of New Jersey (2002); my doctoral research examined the role of inflammatory mediators and NFκB in the acetaminophen-induced model of acute oxidative-stress-mediated hepatotoxicity.
Chem Res Toxicol. 2016 Apr 18;29(4):452-72.
My focus is to advance safe drugs and contribute to the science of toxicology through rigorous issue investigation that informs decisions. To enable this, our group continually evaluates new technologies and strategic approaches that are backed by rigorous science.